[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-headache\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-headache":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,69,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100639640","phase-4-dexamethasone-plus-metoclopramide-versus-paracetamolnsaids-for-primary-headache-100639640",false,"NCT07605065","Dexamethasone Plus Metoclopramide Versus Paracetamol\u002FNSAIDs for Primary Headache","Comparison of Efficacy of Combination Dexamethasone With Metoclopramide Versus Paracetamol\u002FNSAIDs for Treatment of Primary Headache in ED at Tertiary Care Hospital: A Randomized Controlled Trial","DMPH","Inclusion Criteria:\n\n* Patients aged 18 to 60 years.\n* Patients presenting with primary headache diagnosed clinically.\n* Patients presenting within 72 hours of onset of headache.\n* Patients with Visual Analogue Scale (VAS) pain score ≥5.\n\nExclusion Criteria:\n\n* Patients with secondary headache disorders.\n* Patients with known allergy to dexamethasone, metoclopramide, paracetamol, or NSAIDs.\n* Pregnant females.\n* Patients with hepatic impairment.\n* Patients with renal impairment.\n* Patients with peptic ulcer disease or gastrointestinal bleeding.\n* Patients with extrapyramidal disorders.\n* Patients already receiving corticosteroids within previous 48 hours.","ALL","18 Years","60 Years",{"count":21,"type":22},94,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Primary headache disorders are among the most common neurological conditions presenting to emergency departments and can significantly impair quality of life and daily functioning. Various medications are used for acute headache treatment, including paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), metoclopramide, and corticosteroids.\n\nThis randomized controlled trial aims to compare the efficacy of intravenous dexamethasone combined with metoclopramide versus intravenous paracetamol\u002FNSAIDs in patients presenting with primary headache to the emergency department of Pak Emirates Military Hospital, Rawalpindi.\n\nA total of 94 patients aged 18 to 60 years with clinically diagnosed primary headache will be enrolled and randomized into two groups. Group A will receive intravenous dexamethasone 8 mg plus intravenous metoclopramide 10 mg, while Group B will receive intravenous paracetamol or NSAIDs according to departmental protocol. Pain severity will be assessed using the Visual Analogue Scale (VAS) before treatment and again after 60 minutes. Treatment efficacy will be defined as at least 50% reduction in pain score from baseline.\n\nThe results of this study may help identify a more effective treatment strategy for acute primary headache management in emergency departments.",[28],"Primary Headache",[30,31,32,33],"Dexamethasone","Metoclopramide","Paracetamol","NSAIDs","NOT_YET_RECRUITING","2026-05-17",{"date":37,"type":38},"2026-05-22","ACTUAL",{"date":40,"type":22},"2026-11-01",{"date":42,"type":22},"2027-11-01",{"name":44,"class":45},"Pak Emirates Military Hospital","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":18,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100602494","the-impact-of-social-anxiety-on-adolescents-diagnosed-with-primary-headache-a-case-control-study-100602494","NCT07124234","The Impact of Social Anxiety on Adolescents Diagnosed With Primary Headache: A Case-control Study","Assessment of the Impact of Social Anxiety on Primary Headache in Adolescents: A Case-Control Study","Inclusion Criteria:\n\n* Adolescents aged 12-18 years\n* Case group: Participants who will be diagnosed with primary headache according to InternationalClassification of Headache Disorders, 3rd edition (ICHD-3) criteria, confirmed by a pediatric neurologist\n* Control group: Participants who will have no history of recurrent headache or chronic physical\u002Fpsychiatricillness\n\nExclusion Criteria:\n\n* History of neurological disease other than primary headache\n* Any previously diagnosed psychiatric disorders\n* Regular use of psychotropic medications\n* Cognitive or developmental disabilities that would interfere with assessments","12 Years",{"count":55,"type":22},200,"1 Day","OBSERVATIONAL","This case-control study will examine whether adolescents aged 12-18 years with a diagnosis of primary headache are more likely to experience elevated social anxiety compared to matched healthy controls. Social anxiety will be assessed using the SAS-A, and the study will also explore whether environmental and sociodemographic factors such as tobacco smoke exposure, BMI, and parental education influence this relationship.",[28,60],"Social Anxiety Disorder","2025-08-08",{"date":63,"type":38},"2025-08-15",{"date":63,"type":22},{"date":66,"type":22},"2025-10-15",{"name":68,"class":45},"Konya Necmettin Erbakan Üniversitesi",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100537379","nvns-for-the-prevention-and-treatment-of-primary-headache-100537379","NCT06277063","nVNS for the Prevention and Treatment of Primary Headache","Noninvasive Vagus Nerve Stimulation for the Prevention and Treatment of Primary Headache: a Single-arm Single-center Clinical Trial.","Inclusion Criteria:\n\n1. Patients with migraine, cluster headache and tension-type headache were diagnosed according to Chinese Guidelines for the diagnosis and Treatment of Migraine (2022 edition) and Chinese Guidelines for the diagnosis and treatment of cluster headache (2022 edition).\n2. Age \\>=7 years old, \\\u003C=20 years old;\n3. Patients have experienced headache on 3-15 days per month in the past;\n4. Maintain a stable dose and frequency of medication and do not take new drugs during the course of participating in the trial;\n5. They volunteered to participate in the trial and signed informed consent.\n\nExclusion Criteria:\n\n1. History of secondary headache, aneurysm, intracranial hemorrhage, brain tumor, severe head trauma, drug abuse, addiction, syncope, or seizures;\n2. prior migraine-preventive surgery, cervical vagotomy, or implantation of an electronic or neurostimulator device;\n3. Simultaneous use of other devices (e.g., TENS devices, muscle stimulators);\n4. An implantable medical device in use, such as a pacemaker, hearing aid, or any implantable electronic device;\n5. underwent head and neck nerve block within the past 2 months;\n6. Opioid use (more than 2 days per month); Use of analgesics alone or non-steroidal anti-inflammatory drugs (more than 15 days per month); Or tamoxifen, ergots or combination analgesics (more than 10 days per month);\n7. Patients who underwent cervical vagotomy (cervical vagotomy);\n8. Pediatric patients (under 6 years old); Pregnant women;\n9. Patients with clinically significant hypertension, hypotension, bradycardia or tachycardia;\n10. Patients with congenital heart disease;\n11. Mental\u002Fcognitive disorders, etc.","7 Years","20 Years",{"count":79,"type":22},15,[81],"NA","This study is a single-center, single-arm study. All subjects will receive the same treatment.\n\nChildren and adolescents (7-20 years old) with migraine who met the inclusion criteria will be enrolled as subjects in the experimental group, and the changes in headache scores before and after the intervention will be compared. The intervention method is as follows: ictal intervention, in which subjects will be evaluated for headache improvement after a short intervention during an acute exacerbation. By wearing a vagus stimulator, the stimulating electrode will be located in the concha region rich in vagus nerve fiber endings, and the appropriate stimulation intensity will be adjusted for stimulation.\n\nTherefore, this study will verify the effect of nVNS on the acute treatment of primary headache in children and adolescents. Based on the electrocardiogram and electromyography indicators during the intervention process of nVNS, an objective evaluation system for the improvement of headache by nVNS is established, and the role of stimulation parameters on the effect is further explored to realize the optimization of parameters.",[28,84,85,86,87],"Migraine in Adolescence","Migraine in Children","Cluster Headache","Tension Headache",[89,90,91],"Primary headache","Adolescents","Noninvasive vagus nerve stimulation","RECRUITING","2025-08-06",{"date":95,"type":38},"2025-08-12",{"date":97,"type":38},"2024-12-05",{"date":99,"type":22},"2026-12-30",{"name":101,"class":45},"Nanfang Hospital, Southern Medical University",1,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":110,"enrollmentInfo":111,"targetDuration":19,"studyType":57,"phases":4,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":102},"100584024","clinical-features-and-current-treatment-of-primary-headache-100584024","NCT06883955","Clinical Features and Current Treatment of Primary Headache","Prospective Cohort Study of the Clinical Features and Current Treatment of Primary Headache","Inclusion Criteria:\n\n1. Age is less than 65 years old.\n2. Meets the diagnostic criteria for relevant primary headaches (such as tension-type headache, migraine, cluster headache, trigeminal autonomic cephalalgia, etc.) in the third edition of the International Classification of Headache Disorders (ICHD - 3).\n3. Is willing and able to participate throughout the entire study period and sign the informed consent form.\n4. Has the ability to complete the \"Headache Diary\" independently or with the help of a guardian.\n\nExclusion Criteria:\n\n1. Secondary headache\n2. High - risk populations, such as those with severe heart disease, impaired liver and kidney function, malignant tumors, etc.\n3. Patients with mental illness, cognitive impairment, or those who are unable to cooperate with the research requirements\n4. History of intracranial lesions or other nervous system diseases (including stroke, epilepsy, etc.)","65 Years",{"count":112,"type":22},2000,"This study is a prospective, observational cohort study. The plan of this study is to consecutively enroll 2,000 primary headache patients who meet the inclusion criteria from the neurology outpatient department and inpatient department of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. Basic clinical data registration, various scale evaluations, cranial imaging examinations, and collection of blood and fecal biological samples will be completed. During the 10-year follow-up plan, systematic clinical evaluations of the disease severity, diagnosis and treatment, living ability and health status of patients will be carried out regularly every 6 - 12 months. Imaging and other functional evaluations will be conducted when necessary. Data collection includes:\n\nDemographic data (including age, gender, education, ethnicity, marital status, occupation, etc.); General clinical data (past medical history, medication history, personal history, menstrual and childbearing history, family history, etc.); Clinical data of primary headache: headache frequency, duration, severity (Numeric Rating Scale for pain, NRS), headache-related medication use, drug efficacy and side effects; Scale evaluations: MIDAS, HIT-6, BPI, MSQ, ADL, CDR, PGIC, CGIC, PHQ-4, mTOQ-4, ASC-12, MIBS-4, HARDSHIP, WHO-QOL BREF, HAMD, HAMA, TNQ; Records of neurological imaging examinations, blood sample and fecal sample collection.",[28],[116,117,118,119],"primary headache","prospective cohort study","clinical features","current treatment","2025-03-13",{"date":122,"type":38},"2025-03-19",{"date":124,"type":22},"2025-03-08",{"date":126,"type":22},"2037-12-31",{"name":128,"class":45},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"]